Impax Laboratories says that, beginning July 1, the firm's specialty brand products division will co-promote Wyeth's Pristiq (desvenlafaxine), a serotonin-norepinephrine reuptake inhibitor as a treatment for adult patients with major depressive disorder. Impax Pharmaceuticals will utilize its 66 neurology-focused sales force to promote he product.
Impax Labs entered into a three-year co-promotion agreement with Wyeth in July 2008 to detail a product then to-be named by the drug major for neurologists. Impax will receive a fee for each detail delivered. Other terms of this agreement are confidential and were not disclosed.
Wyeth is in the process of being acquired by US pharmaceutical leviathan Pfizer for $68.0 billion (Marketletter February 2).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze